Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42


Cell Receptor and Cofactor Interactions of the Contact Activation System and Factor XI.

Pathak M, Kaira BG, Slater A, Emsley J.

Front Med (Lausanne). 2018 Mar 21;5:66. doi: 10.3389/fmed.2018.00066. eCollection 2018. Review.


Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent.

Ely LK, Lolicato M, David T, Lowe K, Kim YC, Samuel D, Bessette P, Garcia JL, Mikita T, Minor DL Jr., Coughlin SR.

Structure. 2018 Feb 6;26(2):187-198.e4. doi: 10.1016/j.str.2017.12.010. Epub 2018 Jan 11.


An update on factor XI structure and function.

Mohammed BM, Matafonov A, Ivanov I, Sun MF, Cheng Q, Dickeson SK, Li C, Sun D, Verhamme IM, Emsley J, Gailani D.

Thromb Res. 2018 Jan;161:94-105. doi: 10.1016/j.thromres.2017.10.008. Epub 2017 Oct 10. Review.


Prochemerin cleavage by factor XIa links coagulation and inflammation.

Ge X, Yamaguchi Y, Zhao L, Bury L, Gresele P, Berube C, Leung LL, Morser J.

Blood. 2018 Jan 18;131(3):353-364. doi: 10.1182/blood-2017-07-792580. Epub 2017 Nov 20.


Evaluation of the physiological activity of venom from the Eurasian water shrew Neomys fodiens.

Kowalski K, Marciniak P, Rosiński G, Rychlik L.

Front Zool. 2017 Sep 30;14:46. doi: 10.1186/s12983-017-0230-0. eCollection 2017.


Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation.

Hamad BK, Pathak M, Manna R, Fischer PM, Emsley J, Dekker LV.

J Thromb Haemost. 2017 Sep;15(9):1818-1828. doi: 10.1111/jth.13773. Epub 2017 Aug 9.


Generation and characterization of aptamers targeting factor XIa.

Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA.

Thromb Res. 2017 Aug;156:134-141. doi: 10.1016/j.thromres.2017.06.015. Epub 2017 Jun 9.


Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.

Donkor DA, Bhakta V, Eltringham-Smith LJ, Stafford AR, Weitz JI, Sheffield WP.

Sci Rep. 2017 May 18;7(1):2102. doi: 10.1038/s41598-017-02055-x.


New Tools to Study Contact Activation.

Rosén S.

Front Med (Lausanne). 2016 Nov 22;3:58. eCollection 2016.


The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.

Wheeler AP, Gailani D.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1099-114. doi: 10.1016/j.hoc.2016.05.007. Review.


Hemostasis biomarkers and risk of sepsis: the REGARDS cohort.

Moore JX, Zakai NA, Mahalingam M, Griffin RL, Irvin MR, Safford MM, Baddley JW, Wang HE.

J Thromb Haemost. 2016 Nov;14(11):2169-2176. doi: 10.1111/jth.13446. Epub 2016 Sep 23.


Why factor XI deficiency is a clinical concern.

Wheeler AP, Gailani D.

Expert Rev Hematol. 2016 Jul;9(7):629-37. doi: 10.1080/17474086.2016.1191944. Epub 2016 Jun 24. Review.


Factor XI as a Therapeutic Target.

Gailani D, Gruber A.

Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1316-22. doi: 10.1161/ATVBAHA.116.306925. Epub 2016 May 12. Review.


Factor XI Deficiency Alters the Cytokine Response and Activation of Contact Proteases during Polymicrobial Sepsis in Mice.

Bane CE Jr, Ivanov I, Matafonov A, Boyd KL, Cheng Q, Sherwood ER, Tucker EI, Smiley ST, McCarty OJ, Gruber A, Gailani D.

PLoS One. 2016 Apr 5;11(4):e0152968. doi: 10.1371/journal.pone.0152968. eCollection 2016.


A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain.

Wong SS, Østergaard S, Hall G, Li C, Williams PM, Stennicke H, Emsley J.

Blood. 2016 Jun 9;127(23):2915-23. doi: 10.1182/blood-2015-10-676122. Epub 2016 Mar 22.


Factor XIa inhibitors: A review of the patent literature.

Al-Horani RA, Desai UR.

Expert Opin Ther Pat. 2016;26(3):323-45. doi: 10.1517/13543776.2016.1154045. Review.


A refined model of the genomic basis for phenotypic variation in vertebrate hemostasis.

Ribeiro ÂM, Zepeda-Mendoza ML, Bertelsen MF, Kristensen AT, Jarvis ED, Gilbert MT, da Fonseca RR.

BMC Evol Biol. 2015 Jun 30;15:124. doi: 10.1186/s12862-015-0409-y.


Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH.

Kenawy HI, Boral I, Bevington A.

Front Immunol. 2015 May 6;6:215. doi: 10.3389/fimmu.2015.00215. eCollection 2015. Review.


Factor XI and contact activation as targets for antithrombotic therapy.

Gailani D, Bane CE, Gruber A.

J Thromb Haemost. 2015 Aug;13(8):1383-95. doi: 10.1111/jth.13005. Epub 2015 Jun 16. Review.


Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Al-Horani RA, Gailani D, Desai UR.

Thromb Res. 2015 Aug;136(2):379-87. doi: 10.1016/j.thromres.2015.04.017. Epub 2015 Apr 22.

Supplemental Content

Support Center